HER2-Positive Breast Cancer Treatment | Alleviare

 

Breast cancer is a common type of cancer that affects both men and women. One subtype of breast cancer is HER2-positive breast cancer, which occurs when the cancer cells have an overexpression of a protein called human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer is more aggressive than other types of breast cancer, but there are effective treatment options available.

Treatment for HER2-positive Breast Cancer

It usually involves a combination of surgery, chemotherapy, radiation therapy, and targeted therapy. Here are some of the main treatment options for HER2-positive breast cancer:

Surgery: The main goal of surgery is to remove the cancerous tissue from the breast. The surgery can be a lumpectomy, which involves removing only the tumor and a small amount of surrounding tissue, or a mastectomy, which involves removing the entire breast.

Chemotherapy: Chemotherapy is a type of cancer treatment that uses drugs to kill cancer cells. Chemotherapy is often used before surgery to shrink the tumor and make it easier to remove. It can also be used after surgery to kill any remaining cancer cells.

Radiation therapy: Radiation therapy uses high-energy rays to kill cancer cells. It is usually used after surgery to kill any remaining cancer cells that may be present in the breast tissue.

Targeted therapy: Targeted therapy is a type of cancer treatment that targets specific molecules in cancer cells. In the case of HER2-positive breast cancer, targeted therapy drugs such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are used to target the HER2 protein and prevent it from promoting the growth of cancer cells.

Enhertu (fam-trastuzumab deruxtecan-nxki) is a medication that is used to treat HER2-positive breast cancer. It is specifically used in patients with metastatic HER2-positive breast cancer who have received prior treatment with other anti-HER2 therapies.

In addition to these main treatment options, there are also other treatments that may be used for HER2-positive breast cancer, such as hormone therapy and immunotherapy.

It is important to note that the treatment plan for HER2-positive breast cancer can vary depending on the stage of the cancer, the patient's overall health, and other factors. Patients should discuss their individual treatment options with their healthcare provider to determine the best course of action for their specific situation.

In conclusion, HER2-positive breast cancer is a type of breast cancer that requires a comprehensive treatment plan. While it may be more aggressive than other types of breast cancer, there are effective treatment options available, including surgery, chemotherapy, radiation therapy, and targeted therapy. With early detection and proper treatment, many people with HER2-positive breast cancer are able to achieve remission and lead healthy, active lives.


Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more